公开(公告)号：CA3029926A1

公开(公告)日：2018-02-01

申请号：CA3029926

申请日：2016-07-25

Applicant: SHIZUOKA PREFECTURE

Inventor： MOCHIZUKI TOHRU ,  OHSHIMA KEIICHI ,  HATAKEYAMA KEIICHI ,  YAMAGUCHI KEN ,  NAKAO KANAKO

IPC: G01N33/574

Abstract: The present invention addresses the problem of providing a method for collecting highly accurate diagnostic data and a diagnostic kit, both of which are useful for the diagnosis of the occurrence of extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer. The concentration of CEACAM1 in a blood sample collected from a subject is detected using a diagnostic kit including an antibody capable of binding specifically to CEACAM1 or a labeled product of the antibody or the like, whereby it becomes possible to obtain data from which it is diagnosed that a subject is highly probably suffering from extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer when the concentration of CEACAM1 is higher than that in a blood sample from a normal person or is higher than a given threshold value (cut-off value).

公开(公告)号：CA3029926C

公开(公告)日：2023-01-03

申请号：CA3029926

申请日：2016-07-25

Applicant: SHIZUOKA PREFECTURE

Inventor： MOCHIZUKI TOHRU ,  OHSHIMA KEIICHI ,  HATAKEYAMA KEIICHI ,  YAMAGUCHI KEN ,  NAKAO KANAKO

IPC: G01N33/574

Abstract: An object of the present invention is to provide a method for collecting highly accurate data for diagnosis, useful in diagnosing the presence or absence of extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma, and a kit for diagnosis. When the concentration of CEACAM1 in a blood sample collected from a test subject is detected using a kit for diagnosis comprising an antibody specifically binding to CEACAM1 or a labeled product thereof, or the like and the CEACAM1 concentration is higher than the concentration of CEACAM1 in a blood sample derived from a non-carcinoma control subject or higher than a certain threshold value (cutoff value), data can be collected for diagnosing the test subject as having a high possibility of having extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma.